AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Since the early 1990s, it has become clear that the antiphospholipid syndrome (APS) is not only associated with vascular thrombosis but also with a severe intimal hyperplasia called ‘antiphospholipid arterial vasculopathy’. Such vasculopathy has been recognized as a major contributor to large artery occlusion rather than thrombosis or vasculitis. These lesions are described in many vascular territories, including the coronary, carotid or mesenteric arteries. However, their best morphological characterization was conducted in the kidneys, where these lesions have been called APS nephropathy (APSN). These lesions have been associated with a progressive decline of kidney function leading to end-stage renal failure. Interestingly, APSN recurs after kidney transplantation, sometimes quickly, and reduces the allograft survival rate. The molecular pathways that were involved in the development of such lesions were unknown, and therefore no specific treatment was offered to these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxidative stress and subsequent mTOR activation occurs in various rheumatic diseases257–259.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [258]
Citations
Cites
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198
Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF
Ferns, G. A. A., Raines, E. W., Sprugel, K. H., Motani, A. S., Reidy, M. A., & Ross, R. (1991) · Science · doi:10.1126/science.1653454 · Cited by 1,065
The Pathogenesis of the Antiphospholipid Syndrome
Giannakopoulos, B., & Krilis, S. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1112830 · Cited by 688
Pathogenesis of antiphospholipid syndrome: understanding the antibodies
Meroni, P. L., Borghi, M. O., Raschi, E., & Tedesco, F. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.52 · Cited by 620
Gallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.16.2164 · Cited by 490
Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312890 · Cited by 355
Self-citation
Research works printed but not linked: 2
- Alarcón-Segovia D, 1989, J Rheumatol, 16, 762
- Lie JT, 1989, J Rheumatol, 16, 713
Cited by
Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances
Sciascia, S., Amigo, M.-C., Roccatello, D., & Khamashta, M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.124 · Cited by 209
Corban, M. T., Duarte-Garcia, A., McBane, R. D., Matteson, E. L., Lerman, L. O., & Lerman, A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.058 · Cited by 181
“Moreover, mTORC pathway activation in endothelial cells correlated with aPL titers, and an mTORC pathway inhibitor (sirolimus) prevented recurrent renal allograft vasculopathy in patients with APS (54,55).”
BackgroundPetri, M. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.006 · Cited by 130
The role of mitochondria in rheumatic diseases
Becker, Y. L. C., Duvvuri, B., Fortin, P. R., Lood, C., & Boilard, E. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00834-z · Cited by 81
Moschetti, L., Piantoni, S., Vizzardi, E., Sciatti, E., Riccardi, M., Franceschini, F., & Cavazzana, I. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.849086 · Cited by 73
Metadata
- Authors
- Canaud, G., Legendre, C., & Terzi, F.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Corresponding author
- Canaud, G
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2015-01-27
- Volume
- 24
- Issue
- 3
- Pages
- 227-230
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2110636597
- Cited by
- 32
- References
- 32
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 6 · 2017: 7 · 2016: 2 · 2015: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- antiphospholipid syndrome, intimal hyperplasia, large vessel occlusion, kidney transplantation, end-stage renal disease, vascular thrombosis, molecular pathways
- MeSH terms
- Humans, Vascular Diseases, Antiphospholipid Syndrome, Paracrine Communication, Endothelial Cells, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. https://app.cochat.ai/papers/10.1177/0961203315569336
- The paper
- Canaud, G., Legendre, C., & Terzi, F. (2015). AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. Lupus. https://doi.org/10.1177/0961203315569336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.